CNS Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | $1.34 | $1.34 | $1.34 |
| Q2 2024 | 1 | -$0.10 | -$0.10 | -$0.10 |
| Q3 2024 | 1 | -$0.12 | -$0.12 | -$0.12 |
CNS Pharmaceuticals, Inc. Earnings Date And Information
CNS Pharmaceuticals, Inc. last posted its earnings results on Wednesday, August 14th, 2024. The company reported $-6.72 earnings per share for the quarter, topping analysts' consensus estimates of $-120 by $113.28. The company had revenue of 0 for the quarter and had revenue of 0 for the year. CNS Pharmaceuticals, Inc. has generated $-251 earnings per share over the last year ($-250.19 diluted earnings per share) and currently has a price-to-earnings ratio of -0. CNS Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based on prior year's report dates.
CNS Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/14/2024 | Q2 2024 | -$120.00 | -$6.72 | 113.28 | $0 | $0 |
| 05/15/2024 | Q1 2024 | -$20.61 | $0 | |||
| 04/01/2024 | Q4 2023 | -$53.22 | $6,362 | |||
| 11/14/2023 | Q3 2023 | -$54.14 | $0 | |||
| 08/14/2023 | Q2 2023 | -$51.86 | $0 | |||
| 05/15/2023 | Q1 2023 | -$129.35 | $0 | |||
| 05/01/2023 | Q4 2022 | -$173.09 | $0 | |||
| 11/10/2022 | Q3 2022 | -$2.40 | -$131.52 | -129.12 | $0 | |
| 08/12/2022 | Q2 2022 | -$2.40 | -$2.67 | -0.27 | $0 | |
| 05/13/2022 | Q1 2022 | -$2.15 | $0 | |||
| 03/03/2022 | Q4 2021 | -$0.63 | -$3.18 | -2.55 | $0 | |
| 11/12/2021 | Q3 2021 | -$0.63 | -$4.17 | -3.54 | $0 | |
| 08/13/2021 | Q2 2021 | -$0.48 | -$4.50 | -4.02 | $0 | |
| 05/13/2021 | Q1 2021 | -$4.40 | $0 | |||
| 02/12/2021 | Q4 2020 | -$0.27 | -$5.42 | -5.15 | $0 | |
| 11/12/2020 | Q3 2020 | -$3.60 | -$3.66 | -0.06 | $0 | |
| 08/10/2020 | Q2 2020 | -$2.40 | -$4.51 | -2.11 | $0 | |
| 05/15/2020 | Q1 2020 | -$3.00 | -$3.59 | -0.59 | $0 | |
| 03/12/2020 | Q4 2019 | -$0.90 | -$5.03 | -4.13 | $0 | |
| 12/20/2019 | Q3 2019 | -$0.90 | -$1.56 | -0.66 | $0 |
CNS Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is CNS Pharmaceuticals, Inc.'s earnings date?
CNS Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based off last year's report dates.
-
Did CNS Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, CNS Pharmaceuticals, Inc. (:CNSP) reported $-6.72 earnings per share (EPS) to beat the analysts' consensus estimate of $-120 by $113.28.
-
How can I listen to CNS Pharmaceuticals, Inc.'s earnings conference call?
The conference call for CNS Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read CNS Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for CNS Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much profit does CNS Pharmaceuticals, Inc. generate each year?
CNS Pharmaceuticals, Inc. (:CNSP) has a recorded net income of $0. CNS Pharmaceuticals, Inc. has generated $-251.35 earnings per share over the last four quarters.
-
What is CNS Pharmaceuticals, Inc.'s price-to-earnings ratio?
CNS Pharmaceuticals, Inc. (:CNSP) has a price-to-earnings ratio of -0 and price/earnings-to-growth ratio is -0.
